Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
40%
Ph early_phase_1
3
60%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
3(60.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 13 (60.0%)
N/A2 (40.0%)

Trials by Status

completed360%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
completedearly_phase_1

99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients

NCT02723760
unknownnot_applicable

99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma

NCT04504565
completednot_applicable

99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients

NCT02742168
completedearly_phase_1

99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients

NCT02744729
unknownearly_phase_1

99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients

NCT01737112

Clinical Trials (5)

Showing 5 of 5 trials
NCT02723760Early Phase 1

99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients

Completed
NCT04504565Not Applicable

99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma

Unknown
NCT02742168Not Applicable

99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients

Completed
NCT02744729Early Phase 1

99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients

Completed
NCT01737112Early Phase 1

99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5